← Back to scans

Will Trump make IVF free?

KXFREEIVF-29 · Health · 2026-04-03
10%
Multi-Step
16%
Market Price
-6.0%
Edge
50%
Confidence
Final Rationale
My independent estimate of 7% was built on strong evidence: the Feb 2025 EO was only a study directive, the 90-day deadline passed without follow-up, the White House explicitly said no mandate is planned, and the administration pivoted to voluntary drug discounts rather than free IVF. However, the Devil's Advocate raised valid points I partially accept: (1) ACCEPT the TRICARE pathway deserves more weight (~2% bump) since DoD can adjust benefits administratively and it's a politically easy win; (2) PARTIALLY ACCEPT the timeline criticism — 1022 days is substantial and political dynamics (2026 midterms, 2028 election positioning with women voters) create real catalysts, though the administration's revealed preference for voluntary measures is still informative (~1-2% bump); (3) PARTIALLY ACCEPT that the 'no plan to mandate' statement is weaker evidence over a 3-year horizon than I initially coded it, but it still reflects current institutional direction; (4) REJECT Challenge 5 — the resolution criteria specifically require eliminating the cost of 'at least one IVF cycle,' and drug discounts alone won't satisfy this. The market at 16% likely reflects some optimism about the TRICARE pathway and long timeline, but its low volume and high historical volatility (9%-39% range) suggest it's not highly reliable. I remain below the market because the administration's concrete actions consistently point away from free IVF, and the structural obstacles (intra-GOP personhood opposition, $7-10B annual cost, no legislative vehicle) remain significant.
What Would Change My Mind
A DoD/TRICARE announcement expanding IVF coverage to full cost elimination for military families would push this to 60%+. Introduction of a bipartisan IVF bill with White House support would push to 30-40%. Trump making a specific renewed promise with a timeline or mechanism (not just 'we're looking at it') would push to 20-25%. Conversely, if the Big Beautiful Bill passes without IVF provisions, that would confirm the low estimate.
1. Planning Agent Sonnet
binary politics kalshi_data article_search web_search congress_bills
Sub-questions
IDQuestionWeight
sq1 Has Trump already taken or announced a concrete executive action specifically aimed at making IVF free or fully covered by insurance/federal programs? 35%
sq2 Will Congress pass legislation mandating free IVF coverage that Trump would sign before Jan 20, 2029? 30%
sq3 Will Trump use executive authority (executive order, regulatory change, federal program expansion) to eliminate IVF costs before Jan 20, 2029? 35%
Reasoning Approach
This question centers on whether Trump will follow through on a campaign-era promise to make IVF free. Key distinctions: (1) Trump made public statements supporting IVF during the 2024 campaign, but statements are not actions — the resolution requires an actual action eliminating costs; (2) 'free' IVF could be achieved via executive order mandating federal coverage, regulation of insurance markets, expansion of Medicaid/TRICARE, or congressional legislation; (3) Trump's actual track record on IVF since taking office matters most — has any concrete action been taken? (4) The Republican coalition includes anti-abortion factions that oppose IVF on fetal personhood grounds, creating political headwinds even with Trump's stated support; (5) The timeline is long (until Jan 2029), giving more time but also more political uncertainty; (6) The key reference class is presidential campaign healthcare promises that actually get implemented — historically very low, especially when requiring congressional action or against party factions. Executive action alone faces legal challenges and budget constraints (federal cost of universal IVF coverage would be enormous). The market price from Kalshi will be the most informative data point.
2. Research Execution No LLM
ToolStatusTime
kalshi_data OK 2.08s
article_search OK 1.01s
web_search OK 67.46s
congress_bills OK 0.59s
3. Evidence Synthesis Sonnet · 13 items
#StrengthDirectionSourceClaimPriced In
1 STRONG ↓ DOWN article_search In February 2025, Trump signed an executive order directing the Domestic Policy Council to make recommendations on protecting IVF access and reducing costs within 90 days, but the EO itself did not mandate coverage, eliminate costs, or specify who would pay. Yes
2 STRONG ↓ DOWN article_search The 90-day deadline from the February 2025 EO passed without action or White House follow-up, and as of August 2025 the White House said it had no plan to mandate IVF coverage from insurers. Yes
3 STRONG ↓ DOWN article_search On October 16, 2025, Trump announced a deal with EMD Serono for up to 84% discounts on IVF drugs (Gonal-F, Ovidrel, Cetrotide) to be sold via TrumpRx.gov, and guidance encouraging (not mandating) employers to offer fertility benefits — but no government subsidies or mandates were included. Yes
4 MODERATE ↓ DOWN web_search TrumpRx.gov launched on February 5, 2026, offering steeply discounted IVF drugs, but this reduces drug costs only (drugs typically ~$5,000/cycle) rather than eliminating the total cost of an IVF cycle (typically $15,000–$25,000+). Yes
5 STRONG ↓ DOWN article_search Actions taken so far (drug discounts, voluntary employer guidance) fall well short of making IVF 'free' — there is no mandate, no government payment program, and no elimination of the procedure cost. Yes
6 MODERATE ↓ DOWN congress_bills No IVF-related legislation was found in the congressional bills data; no bill mandating free IVF coverage appears to be advancing in Congress. Yes
7 STRONG ↓ DOWN article_search The White House explicitly stated it has no plan to mandate IVF care from health insurers, despite the campaign pledge, as of August 2025. Yes
8 MODERATE ↓ DOWN article_search Conservative factions within the Republican coalition oppose IVF on fetal personhood grounds, creating internal political headwinds against legislation mandating free IVF coverage. Yes
9 MODERATE ↓ DOWN article_search Several states (Tennessee, California, Virginia, Georgia) are passing their own IVF access/coverage laws, suggesting the legislative action is happening at the state level rather than federally. Yes
10 STRONG ↓ DOWN article_search The October 2025 employer guidance explicitly states the government will not offer subsidies to employers or require that they offer IVF coverage, directly contradicting a path to free IVF via executive regulatory action. Yes
11 MODERATE ↓ DOWN web_search The administration's approach has consistently been voluntary partnerships (drug discounts, voluntary employer guidance) rather than mandates, federal payment programs, or Medicaid/TRICARE expansion for IVF. Yes
12 STRONG ↓ DOWN article_search Trump made explicit campaign pledges in 2024 that 'the government is going to pay for it, or we're going to mandate your insurance company to pay for it,' but none of these specific mechanisms have been implemented over a year into his term. Yes
13 MODERATE — NEUTRAL kalshi_data The Kalshi market KXFREEIVF-29 is priced at 16%, up 3% over the past 30 days but flat over the past 7 days, with an all-time range of 9%–39% over 217 days of data. Yes
Information Gaps
  • No data on whether TRICARE or military health benefits are being expanded to cover IVF — this would be a plausible executive pathway that has not been explored in available evidence.
  • No information on the current status of TrumpRx.gov post-launch (February 2026) — specifically whether uptake is significant and whether additional drug partnerships have been added.
  • No data on any pending regulatory rulemaking by HHS, Labor, or Treasury that could mandate IVF coverage in insurance plans — such rulemaking would take time but could still occur before 2029.
  • No congressional bill tracking specifically for IVF coverage mandates — the congress_bills search returned unrelated bills.
  • Unknown whether the 'Big Beautiful Bill' or other omnibus legislation being discussed in 2025 includes any IVF provisions.
  • No information on whether Medicaid expansion to cover IVF is being considered, which would represent a federal program expansion pathway.
  • No data on Trump's current stated position on IVF post-October 2025 — whether he has reiterated or backed away from the free IVF pledge in more recent statements.
Key Uncertainties
  • Whether the administration will escalate from voluntary/discount measures to a genuine mandate or federal payment program in the remaining ~3 years of Trump's term.
  • Whether the question resolves YES based on partial elimination of costs (e.g., fully covering drug costs only) or requires the entire procedure to be free — the resolution criteria says 'eliminates the cost of at least one IVF cycle,' which is ambiguous about whether drug discounts alone qualify.
  • Whether a TRICARE expansion covering IVF for military families could qualify as 'making IVF free' — this is a narrower but more legally feasible executive pathway.
  • Political dynamics: whether continued political pressure around reproductive rights (post-Dobbs) and pronatalism push could create enough incentive for stronger action.
  • Whether the 30-day price increase on Kalshi (+3%) reflects new information or just noise given low volume.
Market Context
Price: 0.16 · 7d: +0.00 · 30d: +0.03
Volume: LOW · Depth: LOW
Reliability: LOW-MEDIUM — 149 avg daily contracts is modest volume; the 217-day price range of 9%–39% shows significant historical volatility suggesting market has revised substantially based on news events; current flat 7-day trend suggests no new information priced in recently
4. Independent Forecaster Opus · No market price Did NOT see market price
Independent estimate: 7% (high confidence)
sq1: Has Trump already taken or announced a concrete executive action specifically aimed at making IVF free or fully covered by insurance/federal programs?
3%
Base rate: We're looking at whether a concrete action has ALREADY been taken. The evidence is very clear — the February 2025 EO was a study directive only, the 90-day deadline passed without follow-up, the October 2025 announcement was drug discounts only (not free IVF), and the White House explicitly said it has no plan to mandate coverage. TrumpRx.gov reduces drug costs (~$5K of a $15-25K cycle) but doesn't eliminate the cost of a full cycle. The only slim possibility for YES here is if TrumpRx somehow covers the entire cycle cost or if there's been a TRICARE expansion we don't know about. But the evidence strongly indicates no action eliminating the full cost of even one IVF cycle has been taken. P(YES) = 0.03.
sq2: Will Congress pass legislation mandating free IVF coverage that Trump would sign before Jan 20, 2029?
4%
Base rate: Presidential campaign healthcare promises requiring congressional action have a very low implementation rate — perhaps 10-20% even for popular proposals with party support. Here, the situation is worse: no bill has been introduced, the White House itself has said it won't mandate coverage, conservative factions oppose IVF on personhood grounds, Republicans control Congress but are focused on other priorities (tax cuts, immigration, DOGE), and the legislative action on IVF is happening at the state level. The historical reference class of major new federal healthcare mandates passing Congress is very small (ACA being the notable exception, which took enormous political capital). Even with 3 years remaining, the structural obstacles — no bill, no White House push, intra-party opposition — make this extremely unlikely. A midterm election in 2026 could shift Congress to Democrats, who might be more supportive, but a Democratic Congress would face Trump's potential veto of a broader bill. P(YES) = 0.04.
sq3: Will Trump use executive authority (executive order, regulatory change, federal program expansion) to eliminate IVF costs before Jan 20, 2029?
8%
Base rate: Presidents implementing major new benefits via executive action alone is rare, perhaps 5-10% for major campaign promises. The administration has explicitly chosen the voluntary/discount approach rather than mandates. However, the timeline extends to January 2029, giving nearly 3 more years. Possible pathways: (1) TRICARE expansion to cover IVF for military families — this is administratively feasible and could qualify under the resolution criteria ('eliminates the cost of at least one IVF cycle' — even if only for military families). TRICARE already covers some fertility treatments. This pushes UP by ~3%. (2) HHS could issue regulations under the ACA requiring IVF coverage as an essential health benefit — legally complex and would face litigation but possible. This pushes UP by ~1%. (3) A Medicaid waiver or demonstration program could provide free IVF to low-income individuals. Pushes UP by ~1%. Against these: the administration has actively signaled it won't mandate coverage, DOGE-era budget cutting makes new spending programs unlikely, and the political dynamics within the GOP haven't changed. The key uncertainty is TRICARE — if DoD expanded TRICARE to fully cover IVF for servicemembers, this would likely qualify and is within executive authority. But even this hasn't been signaled. P(YES) = 0.08.
Show full reasoning trace
base rate: Presidential campaign healthcare promises that get fully implemented: roughly 10-25% for popular, party-aligned proposals. But 'make IVF free' faces unique headwinds: no party consensus (personhood opposition within GOP), enormous cost (~$7-10B/year if broadly available), no existing legislative vehicle, and the administration itself has backed away from mandates. The base rate for this specific type of promise — a costly new benefit opposed by factions within the president's own party — is probably closer to 5-10%.
evidence updates: The February 2025 EO was a study directive, not action (neutral-to-slightly-down). The 90-day deadline passing without follow-up is STRONG evidence DOWN (-5-10%). The White House explicitly saying no mandate planned is STRONG evidence DOWN (-5-10%). The TrumpRx drug discount approach signals the administration's preferred pathway is voluntary/market-based, not government-funded (-3-5%). No congressional bills advancing is moderate DOWN (-3%). State-level action suggests federal action is less likely (-2%). The remaining 3-year timeline pushes slightly UP (+2-3%) as conditions could change. TRICARE expansion remains an unexplored but plausible pathway (+1-2%).
combination method: The question resolves YES if ANY pathway succeeds. I used a combination of weighted average and maximum approaches, adjusted for positive correlation between sub-questions (all depend on Trump administration willingness to act). The correlation adjustment is significant — if the administration won't mandate coverage (as stated), all pathways become less likely simultaneously.
final: Despite Trump's explicit 2024 campaign promise, over a year into his term the administration has taken only voluntary/discount measures and explicitly stated it won't mandate coverage. The structural obstacles (intra-party opposition, budget constraints, no legislative vehicle) remain significant. The 3-year remaining timeline provides some possibility for change, particularly via TRICARE expansion or a surprise legislative deal, but the current trajectory strongly suggests the promise won't be fulfilled in its literal form. I estimate a 7% probability.
5. Devil's Advocate Sonnet Market price revealed
Asymmetric Evidence Missing Info Time Awareness Issue
Challenges
  1. The forecaster's TRICARE pathway deserves more weight than given. TRICARE expansion for military families is well within executive authority, has bipartisan support, and would clearly satisfy the resolution criteria ('eliminates the cost of at least one IVF cycle' for a defined population). The forecaster acknowledges this but only adds 3% for it. Given that DoD regularly adjusts TRICARE benefits administratively, and this would be a politically easy win that Trump could claim fulfills his promise, this pathway alone might warrant 5-8%.
  2. The 1022-day remaining timeline is substantial — nearly 3 years. The forecaster acknowledges this adds 2-3% but may be underweighting the sheer number of possible catalysts over that period: midterm elections in 2026 could create political pressure, a Democratic Congress could pass a bill Trump might sign for populist credit, or Trump could make a pre-2028 announcement to shore up support among women voters. The forecaster treats the current trajectory as highly predictive of future action, but political dynamics shift substantially over 3-year windows.
  3. The forecaster heavily weights the White House's statement that it has 'no plan to mandate coverage' as strong evidence against resolution. But political statements about current plans are poor predictors of actions 1-3 years out. The Obama administration initially said it wouldn't mandate an individual health insurance requirement, then did. Politicians frequently reverse stated positions. This evidence should be moderate, not strong.
  4. The correlation adjustment in the combination method may be too aggressive. The forecaster notes that 'if the administration won't mandate coverage, all pathways become less likely simultaneously.' But the legislative pathway (sq2) could proceed independently of executive will — a bipartisan or Democratic Congress could pass a bill that Trump signs for political credit even if his administration didn't initiate it. The pathways are correlated but not as tightly as suggested.
  5. The resolution criteria are potentially more generous than the forecaster assumes. The question asks if Trump will 'make IVF free' — if TrumpRx drug discounts are expanded significantly AND combined with additional measures (employer guidance, state-level mandates enabled by federal action, partial coverage mandates), there could be a pathway where the aggregate effect is judged to satisfy the resolution criteria, even if no single action eliminates 100% of costs. The forecaster should consider how the resolution will actually be adjudicated.
  6. The information gaps identified are significant and should widen uncertainty rather than leave the forecast low. The forecaster identifies no data on TRICARE expansion, pending HHS rulemaking, Big Beautiful Bill provisions, Medicaid expansion considerations, or Trump's recent stated position — all of which could contain positive signals. When you have this many unknown-unknowns, the forecast should carry more uncertainty (i.e., be pulled somewhat toward the prior/base rate rather than being so confident in the negative direction).
Suggested adjustment: +3pp
The forecaster underweights the long remaining timeline (1022 days), the TRICARE executive pathway, the unreliability of current White House statements as predictors of future action, and the significant information gaps that should widen uncertainty upward from 7%. The evidence is overwhelmingly down-coded, but several of those 'strong down' signals (like the White House saying 'no plan') are weaker than claimed over a 3-year horizon. A modest upward adjustment to ~10% is warranted based on these reasoning flaws.
Market comparison: Forecaster: 7%, Market: 16%. The 9-point divergence is notable. The market has low volume and reliability, so it shouldn't be treated as highly informative. However, the forecaster's reasoning does contain genuine flaws (overweighting current political statements, underweighting the long timeline and TRICARE pathway, and not adequately reflecting the large information gaps). These flaws justify a modest upward adjustment toward ~10%, but not all the way to the market price. The remaining divergence from the market (~6%) could reflect the market overpricing the chance or the forecaster's legitimately strong evidence about the administration's revealed preferences.
6. Final Forecast Opus
10% (medium confidence)
My independent estimate of 7% was built on strong evidence: the Feb 2025 EO was only a study directive, the 90-day deadline passed without follow-up, the White House explicitly said no mandate is planned, and the administration pivoted to voluntary drug discounts rather than free IVF. However, the Devil's Advocate raised valid points I partially accept: (1) ACCEPT the TRICARE pathway deserves more weight (~2% bump) since DoD can adjust benefits administratively and it's a politically easy win; (2) PARTIALLY ACCEPT the timeline criticism — 1022 days is substantial and political dynamics (2026 midterms, 2028 election positioning with women voters) create real catalysts, though the administration's revealed preference for voluntary measures is still informative (~1-2% bump); (3) PARTIALLY ACCEPT that the 'no plan to mandate' statement is weaker evidence over a 3-year horizon than I initially coded it, but it still reflects current institutional direction; (4) REJECT Challenge 5 — the resolution criteria specifically require eliminating the cost of 'at least one IVF cycle,' and drug discounts alone won't satisfy this. The market at 16% likely reflects some optimism about the TRICARE pathway and long timeline, but its low volume and high historical volatility (9%-39% range) suggest it's not highly reliable. I remain below the market because the administration's concrete actions consistently point away from free IVF, and the structural obstacles (intra-GOP personhood opposition, $7-10B annual cost, no legislative vehicle) remain significant.
Pipeline Timing
StepTime
Planning 15.18s
Research 67.46s
Synthesis 39.35s
Forecaster 37.8s
Critic 25.36s
Final 12.7s